THERANEXUS and BBDF present progress on the Batten-1 program at the Translational Research Conference for the Management OF NCLs on 3 and 4 November, 2022 in Chicago

02/11/2022

Download PDF File(<1Mo)

Theranexus and inserm TRANSFERT sign a strategic alliance to identify advanced therapy drug candidates for rare neurological diseases

20/10/2022

Download PDF File(<1Mo)

THERANEXUS publishes its cash position as of 30 September 2022

19/10/2022

Download PDF File(<1Mo)

THERANEXUS announces its financial result for the first half of 2022

27/09/2022

Download PDF File(<1Mo)

THERANEXUS and BBDF finalize recruitment for phase I/II trial to evaluate Batten-1 in Batten disease

08/09/2022

Download PDF File(412Ko)

Semi-annual liquidity contract summary

17/07/2022

Download PDF File(353Ko)

Theranexus publishes its cash position as of 30 June 2022

12/07/2022

Download PDF File(253Ko)

Theranexus participates in several leading scientific conferences and business conventions

09/06/2022

Download PDF File(253Ko)

THERANEXUS publishes its 2021 full-year results and announces a shift of its strategic focus to rare neurological diseases

25/04/2022
Download PDF File (276Ko)

Information on the number of shares composing share capital

06/04/2022
Download PDF File (276Ko)

Information on the number of shares composing share capital

23/03/2022
Download PDF File (276Ko)

THERANEXUS unveils its scientific advances on the occasion of World Rare Disease Day 2022

24/02/2022
Download PDF File (544Ko)

Information on the number of shares composing share capital

10/02/2022
Download PDF File (276Ko)

THERANEXUS and BBDF start recruitment for phase I/II trial in Batten disease patients

03/02/2022
Download PDF File (373Ko)

THERANEXUS publishes its cash position as of 31 December 2021

13/01/2022
Download PDF File (355Ko)

Semi-annual liquidity contract summary

06/01/2022
Download PDF File (383Ko)

Information on the number of shares composing share capital

04/01/2022
Download PDF File (383Ko)